ArticleJTO clinical and research reports2023
Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor-Based Systemic Therapy in
Article in JTO clinical and research reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 17 citations in OpenAlex.
- Encorafenib plus binimetinib for BRAF V600E-mutant metastatic NSCLC: clinical implications of the phase 2 PHAROS study.Future oncology (London, England) · 2024Trial
- Influence of oncogenic drivers and signaling pathways on immune checkpoint inhibitor efficacy in NSCLC.Genes & diseases · 2027Review
- The value of real-world evidence in supporting targeted therapies for patients with rare oncogenic drivers in mNSCLC.Future oncology (London, England) · 2025Review
- Proceedings of the 1st biannual bridging the gaps in lung cancer conference.The oncologist · 2025Article
- Association of systemic therapy with survival among adults with advanced non-small cell lung cancer.Translational lung cancer research · 2025Article
- Outcomes with frontline immune checkpoint inhibitors among individuals withFrontiers in oncology · 2025Article
- Effects of chemotherapy combined with immunotherapy for non-small cell lung cancer withAmerican journal of cancer research · 2025Article
- Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer Under-Represented by Clinical Trials.Current oncology (Toronto, Ont.) · 2024Review
- BRAFNPJ precision oncology · 2024Review
- Clinicopathological Features of Non-Small Cell Lung Carcinoma with BRAF Mutation.Current oncology (Toronto, Ont.) · 2023Article
- Real-World Treatment Patterns and Outcomes of First-Line Immunotherapy Among Patients With Advanced Nonsquamous NSCLC HarboringJTO clinical and research reports · 2023Article
- Molecular mechanism and clinical outcome of non-small cell lung cancer patients with high BRAF expression.Translational lung cancer research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Methods: Demographic, clinical, treatment, and outcome data of patients with Results: A total of 53 Conclusions: This study of real-world patients with
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.